Welcome!

News Feed Item

Dr. Jeanne M. Novak, President & CEO Of CBR International Corp.®, To Attend World Health Organization (WHO) Meeting To Address Leading Experimental Treatments And Vaccines For The Ebola Virus, September 4 - 5, 2014, Geneva, Switzerland

CBR International's Scientific Experts Supporting Mapp Biopharmaceutical Pertaining to ZMAPP™

BOULDER, Colo., Sept. 2, 2014 /PRNewswire/ -- Dr. Jeanne M. Novak, President and CEO of Boulder, Colorado-based CBR International Corp.®, a full-service biopharmaceutical product, clinical, medical device and regulatory development and compliance group, has been invited by Dr. Larry Zeitlin, President of Mapp Biopharmaceutical to attend the World Health Organization's Investigational Treatment for Ebola conference in Geneva, Switzerland, September 4 – 5. Over the last several months, CBR International's expert team of clinical, regulatory and scientific consultants has been supporting and collaborating with Mapp Biopharmaceutical, Inc., the San Diego-based biotech company responsible for developing ZMappTM, the monoclonal antibody cocktail that has been employed for compassionate use in the current Ebola outbreak.

Working side-by-side with Mapp Biopharmaceutical, Inc.,  Kentucky Bioprocessing (KBP), Emory University Hospital (Atlanta), ELWA Hospital (Paynesville City/Monrovia, Liberia), London's Royal Free Hospital (UK) and the U.S. Food and Drug Administration (FDA), CBR International has helped to ensure that the proper dosing, safety monitoring and all regulatory procedures were followed for the administration of ZMapp.

"CBR International Corp. has been committed to supporting Mapp Biopharmaceutical during the emergency use of the investigational product," said Dr. Jeanne M. Novak, President and CEO of CBR International Corp. "We will continue to support Mapp throughout its ongoing clinical development while also lending our expertise to the myriad of other affiliated health and regulatory organizations during this crisis."

Dr. Kevin Whaley, CEO of Mapp Biopharmaceutical noted that, "Without the collaboration and support of CBR International associates, especially Dr. Jeanne M. Novak, Dr. Miles Brennan, Mr. Kevin Hennegan, Dr. Tara Nyhuis, Dr. James Merritt, and Dr. Dana Weinberger, patients may not have had the opportunity to volunteer to receive ZMapp."

The WHO meeting in Geneva will address leading experimental treatments and vaccines for Ebola, including potential risks and benefits, short- and long-term availability, potential use and key considerations for deployment in West Africa, as well as clinical testing and ethics. Its goal is to help develop strategies to pave the road for future Ebola preparedness.

About Dr. Jeanne M. Novak
Dr. Jeanne M. Novak founded CBR International Corp. in 1999 (originally Colorado BioReg). She is an internationally-recognized authority in the biotechnology and pharmaceutical industries and is currently consulting in numerous product development areas including recombinant biotechnology, naturally-derived products, cell and gene therapy, devices and vaccines. She is an author, lecturer and strategic development advisor to industry executives worldwide.

Additionally, Dr. Novak has almost 20 years of experience in product and assay development and validation, clinical trial design and oversight, quality assurance systems development, cGMP manufacturing and compliance and global regulatory development to advise cost and time-optimized development for new and established biotech and pharma companies.

Prior to founding CBR International, Dr. Novak served as Senior Scientist in the Center for Biologics Evaluation and Research (CBER) responsible for several programs and policy development.  Before joining the FDA, Dr. Novak conducted scientific research in the area of recombinant vaccine development at United States Army Medical Research Institute of Infectious Diseases.

Dr. Novak received a Ph.D. in Experimental Pathology (Cell Biology) and Immunology and a B.S. in Biology from the University of Utah.

About CBR International Corp.
CBR International Corp. is a full-service product, clinical, and strategic regulatory group dedicated to providing comprehensive product development services to the biotechnology, pharmaceutical, and device industries worldwide. The Company's expert staff of scientists is experienced in an all-encompassing range of indications for drugs, novel antibodies, recombinant protein therapeutics, small molecules, vaccines, cell therapy, devices and combination products throughout all phases of program development and commercialization. For more information, please visit www.cbrintl.com.

SOURCE CBR International Corp.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
NHK, Japan Broadcasting, will feature the upcoming @ThingsExpo Silicon Valley in a special 'Internet of Things' and smart technology documentary that will be filmed on the expo floor between November 3 to 5, 2015, in Santa Clara. NHK is the sole public TV network in Japan equivalent to the BBC in the UK and the largest in Asia with many award-winning science and technology programs. Japanese TV is producing a documentary about IoT and Smart technology and will be covering @ThingsExpo Silicon Val...
The Internet of Things is clearly many things: data collection and analytics, wearables, Smart Grids and Smart Cities, the Industrial Internet, and more. Cool platforms like Arduino, Raspberry Pi, Intel's Galileo and Edison, and a diverse world of sensors are making the IoT a great toy box for developers in all these areas. In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists discussed what things are the most important, which will have the most profound e...
SYS-CON Events announced today that Twistlock, the leading provider of cloud container security solutions, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Twistlock is the industry's first enterprise security suite for container security. Twistlock's technology addresses risks on the host and within the application of the container, enabling enterprises to consistently enforce security policies, monitor...
With billions of sensors deployed worldwide, the amount of machine-generated data will soon exceed what our networks can handle. But consumers and businesses will expect seamless experiences and real-time responsiveness. What does this mean for IoT devices and the infrastructure that supports them? More of the data will need to be handled at - or closer to - the devices themselves.
Multiple data types are pouring into IoT deployments. Data is coming in small packages as well as enormous files and data streams of many sizes. Widespread use of mobile devices adds to the total. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will look at the tools and environments that are being put to use in IoT deployments, as well as the team skills a modern enterprise IT shop needs to keep things running, get a handle on all this data, and deli...
Automation is enabling enterprises to design, deploy, and manage more complex, hybrid cloud environments. Yet the people who manage these environments must be trained in and understanding these environments better than ever before. A new era of analytics and cognitive computing is adding intelligence, but also more complexity, to these cloud environments. How smart is your cloud? How smart should it be? In this power panel at 20th Cloud Expo, moderated by Conference Chair Roger Strukhoff, pane...
In recent years, containers have taken the world by storm. Companies of all sizes and industries have realized the massive benefits of containers, such as unprecedented mobility, higher hardware utilization, and increased flexibility and agility; however, many containers today are non-persistent. Containers without persistence miss out on many benefits, and in many cases simply pass the responsibility of persistence onto other infrastructure, adding additional complexity.
Building a cross-cloud operational model can be a daunting task. Per-cloud silos are not the answer, but neither is a fully generic abstraction plane that strips out capabilities unique to a particular provider. In his session at 20th Cloud Expo, Chris Wolf, VP & Chief Technology Officer, Global Field & Industry at VMware, will discuss how successful organizations approach cloud operations and management, with insights into where operations should be centralized and when it’s best to decentraliz...
SYS-CON Events announced today that Grape Up will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company specializing in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the U.S. and Europe, Grape Up works with a variety of customers from emergi...
@ThingsExpo has been named the Most Influential ‘Smart Cities - IIoT' Account and @BigDataExpo has been named fourteenth by Right Relevance (RR), which provides curated information and intelligence on approximately 50,000 topics. In addition, Right Relevance provides an Insights offering that combines the above Topics and Influencers information with real time conversations to provide actionable intelligence with visualizations to enable decision making. The Insights service is applicable to eve...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
Back in February of 2017, Andrew Clay Schafer of Pivotal tweeted the following: “seriously tho, the whole software industry is stuck on deployment when we desperately need architecture and telemetry.” Intrigue in a 140 characters. For me, I hear Andrew saying, “we’re jumping to step 5 before we’ve successfully completed steps 1-4.”
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...